Mortality Patterns of Synchronous Uterine and Ovarian Cancers: A SEER Registry Analysis.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
02 11 2022
02 11 2022
Historique:
received:
19
05
2022
revised:
04
08
2022
accepted:
11
08
2022
pubmed:
20
8
2022
medline:
4
11
2022
entrez:
19
8
2022
Statut:
ppublish
Résumé
The degree to which uterine cancer metastatic to the ovary is misdiagnosed as synchronous stage I uterine and ovarian cancers is unclear. We sought to determine whether patients with synchronous cancers had mortality patterns similar to either stage IIIA uterine, stage I uterine, or stage I ovarian cancers alone. The Surveillance, Epidemiology, and End Results database was used to compare mortality of patients with synchronous stage I uterine and stage I ovarian cancers versus those with stage IIIA uterine, stage I uterine, or stage I ovarian cancers alone. We calculated age-adjusted mortality hazard ratios (HR) and 95% confidence intervals (CI) accounting for calendar year and grade, adjuvant treatment, grade 1 endometrioid cancers, grade 3 endometrioid cancers, and stage IA cancers. Among the 9,321 patients, we observed lower age-adjusted mortality in patients with stage I synchronous cancers (n = 937) compared to those with stage IIIA uterine (n = 531; HR, 0.45 95% CI, 0.35-0.58), stage I uterine (n = 6,919; HR, 0.74; 95% CI, 0.60-0.91), and stage I ovarian cancers (n = 934; HR, 0.52; 95% CI, 0.41-0.67). Results were similar after taking into account diagnosis year and grade, and limiting to those receiving adjuvant therapy, grade 1 or grade 3 endometrioid cancers, or stage IA cancers. We observed lower mortality for synchronous stage I uterine and ovarian cancers, which was not explained by younger age, earlier stage, lower grade, histology type, or adjuvant therapy. The possible misdiagnosis associated with clinicopathologic of synchronous uterine and ovarian cancers does not appear to worsen survival on a population level.
Sections du résumé
BACKGROUND
The degree to which uterine cancer metastatic to the ovary is misdiagnosed as synchronous stage I uterine and ovarian cancers is unclear. We sought to determine whether patients with synchronous cancers had mortality patterns similar to either stage IIIA uterine, stage I uterine, or stage I ovarian cancers alone.
METHODS
The Surveillance, Epidemiology, and End Results database was used to compare mortality of patients with synchronous stage I uterine and stage I ovarian cancers versus those with stage IIIA uterine, stage I uterine, or stage I ovarian cancers alone. We calculated age-adjusted mortality hazard ratios (HR) and 95% confidence intervals (CI) accounting for calendar year and grade, adjuvant treatment, grade 1 endometrioid cancers, grade 3 endometrioid cancers, and stage IA cancers.
RESULTS
Among the 9,321 patients, we observed lower age-adjusted mortality in patients with stage I synchronous cancers (n = 937) compared to those with stage IIIA uterine (n = 531; HR, 0.45 95% CI, 0.35-0.58), stage I uterine (n = 6,919; HR, 0.74; 95% CI, 0.60-0.91), and stage I ovarian cancers (n = 934; HR, 0.52; 95% CI, 0.41-0.67). Results were similar after taking into account diagnosis year and grade, and limiting to those receiving adjuvant therapy, grade 1 or grade 3 endometrioid cancers, or stage IA cancers.
CONCLUSIONS
We observed lower mortality for synchronous stage I uterine and ovarian cancers, which was not explained by younger age, earlier stage, lower grade, histology type, or adjuvant therapy.
IMPACT
The possible misdiagnosis associated with clinicopathologic of synchronous uterine and ovarian cancers does not appear to worsen survival on a population level.
Identifiants
pubmed: 35984988
pii: 710032
doi: 10.1158/1055-9965.EPI-22-0587
pmc: PMC9633557
mid: NIHMS1831952
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2038-2045Subventions
Organisme : NICHD NIH HHS
ID : K12 HD085816
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA042014
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA243188
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR002540
Pays : United States
Informations de copyright
©2022 American Association for Cancer Research.
Références
Int J Cancer. 2020 Jul 15;147(2):478-489
pubmed: 32022266
Int J Gynaecol Obstet. 2008 Jul;102(1):34-8
pubmed: 18342863
Int J Gynecol Pathol. 2014 May;33(3):274-81
pubmed: 24681739
Oncotarget. 2018 Jun 19;9(47):28757-28771
pubmed: 29983894
Obstet Gynecol. 2009 Apr;113(4):783-789
pubmed: 19305320
Int J Gynecol Cancer. 2018 May;28(4):704-712
pubmed: 29498984
Cancer. 2014 Dec 1;120 Suppl 23:3836-45
pubmed: 25412395
BMJ. 2010 Mar 12;340:b5087
pubmed: 20228141
Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):403-7
pubmed: 18990010
Obstet Gynecol. 2005 Oct;106(4):693-9
pubmed: 16199623
Gynecol Oncol. 2018 Jul;150(1):92-98
pubmed: 29716739
J Clin Oncol. 2007 Nov 20;25(33):5158-64
pubmed: 17925543
Arch Gynecol Obstet. 2012 Nov;286(5):1241-5
pubmed: 22688443
Gynecol Oncol. 2004 Aug;94(2):456-62
pubmed: 15297188
Gynecol Oncol. 2017 Dec;147(3):558-564
pubmed: 28986093
J Obstet Gynaecol Res. 2015 Nov;41(11):1813-9
pubmed: 26369625
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
J Natl Cancer Inst. 2016 Feb 01;108(6):djv428
pubmed: 26832771
Hum Pathol. 2019 Mar;85:92-100
pubmed: 30448219